ABSTRACT
INTRODUCTION
Soluble guanylyl cyclase (sGC) is a ubiquitous enzyme that converts GTP to the second messenger molecule cGMP (12, 15) . cGMP modifies the activity of protein kinases, phosphodiesterases and ion channels to change the behavior of cells and tissues(21). sGC is a heterodimeric protein that consists of an alpha and a beta subunit; the holoenzyme also contains a molecule of heme that serves as a sensor for nitric oxide(15). Binding of NO to the heme moiety of sGC increases dramatically its catalytic activity(21). Both genetic and pharmacological approaches have proven the importance of sGC in reducing smooth muscle tone and inhibiting platelet aggregation(21, 22).
Although, many small molecules with sGC stimulating activity have been identified, and are extensively used in vitro and in vivo, there are only two chemically related sGC inhibitors, namely ODQ and NS-2028(14, 27). Their mechanism of action is believed to involve oxidation of the heme moiety, thus, making sGC unresponsive to the action of NO. Between the two, ODQ is by far the most widely used inhibitor of sGC, but its use in vivo has been limited. To the best of our knowledge NS-2028 has yet to be used in vivo,.
Lack of experimental evidence with sGC inhibitors in animal studies has limited our ability to determine the contribution of sGC in physiological and pathophysiological conditions in vivo.
Angiogenesis, the process of blood vessel formation from existing structures, is tightly regulated in adult organisms (3, 11) . In fact, angiogenesis occurs only in a few physiological settings, such as those associated with wound healing and normal ovary cycling (4) . Angiogenesis is a crucial adaptive response to exercise training and also critical for the survival of ischemic tissues as it helps in collateral vessel formation (3) . In contrast, excessive or deregulated angiogenic responses contribute to tumor growth, inflammation, destruction of the retina in diabetes, and are important for the pathogenesis of psoriasis and arthritis (4) . Vascular endothelial growth factor (VEGF) is a key modulator of angiogenesis promoting endothelial cell migration, proliferation, and survival(9). A number of studies have proposed that NO plays a permissive role for angiogenesis and that it mediates many of the angiogenic effects of VEGF in vitro and in vivo (13, 24, 28, 39, 40) . Results from experiments with cultured EC suggest that some of the angiogenic actions of NO are dependent on cGMP formation (29, 30, 39) and GMPelevating agents have the ability to enhance EC migration(30, 32). However, cGMPindependent angiogenic actions of VEGF and NO have also been described(6, 31). The aim of the present study was to determine which of the VEGF-triggered angiogenesis related properties are sGC-dependent and to investigate whether sGC contributes to VEGF-stimulated angiogenesis and permeability in vivo.
the protein synthesis inhibitor cycloheximide (Sigma-Aldrich). After 24 or 48 hr, both floating and adherent cells were collected and washed twice with PBS. Cells were then lysed in a buffer containing 10mM Tris, pH 7.5, 100mM NaCl, 1mM EDTA and 0.01% Triton X-100. The fluorescence of the cleaved reporter group was measured 30 min after the addition of 100μΜ substrate at 380 nm excitation and 469 nm emission. Relative fluorescence unit (RFU) data were normalized per mg protein.
Cell Migration
Cells were serum-starved and subsequently treated with NS-2028 (10 μΜ), the p38 inhibitor SB203580 (3 μΜ) or vehicle for 30 min prior to trypsinization. After 
Western blotting
After the indicated treatments, proteins were extracted after homogenization in a lysis buffer containing 1% Triton-X, 1% SDS, 150mM NaCl, 50mM NaF, 1mM Na 3 VO 4 , 0.5% sodium deoxycholate, 1mM EDTA, 0.1mM EGTA and protease inhibitors: 10 μg/ml aprotinin, 10 μg/ml pepstatin and 20 mM PMSF (all from Sigma-Aldrich, St Luis, MO). Samples were subjected to SDS-PAGE, transferred to an activated PVDF membrane and incubated with the indicated primary Ab (anti phospho-eNOS and eNOS antibodies, anti phospho-tyrosine, phospho-p38, p38, phospho-ERK1/2 and ERK1/2 antibodies, obtained from Cell Signalling Technology, Beverly, MA; and anti KDR antibody, from Upstate, Lake Placid, NY, USA) and appropriate secondary antibodies (Cell Signalling Technology or Sigma-Aldrich). Immunoreactive proteins were detected using a chemiluminescent substrate (Pierce Biotechnology, Rockford, IL). DC Protein assay kit and immunoblotting reagents were from Bio-Rad Laboratories (Hercules, CA).
Rat aorta ring assay
Aortas from Wistar rats (Charles River, Calco, Como, Italy) were isolated in sterile conditions. Rings 1-2 mm long were produced and included in a fibrin gel obtained by adding 400 µl of a bovine fibrinogen solution (3 mg/ml in M199 medium; SigmaAldrich) into each well of 48-multiwell plates. Gelation of the fibrinogen was induced with bovine thrombin (1.5 units/ml; Sigma-Aldrich). After 20 min, 400 µl of M199 medium was added with antibiotics (100 units/ml penicillin and 100 µg/ml streptomycin), amphotericin B (0.25 µg/ml), and 10% FCS were added to each well. After 24 h, the medium was removed, the gels washed, and NS-2028 (10 μΜ) or vehicle (medium supplemented with 1% FCS and DMSO) was added for 30 min followed by treatment with VEGF or bFGF (50 ng/ml) or medium for 72 hr. Quantitative evaluation of newly formed structures was carried out on day 3. At a magnification of 200, the area occupied by tubules was measured using an ocular grid (0.21 mm 2 ). The result is expressed as the number of grid units (NGU) (10).
Rabbit cornea in vivo angiogenesis assay
Experiments have been performed in accordance with the guidelines of the European Economic Community for animal care and welfare (EEC Law No. 86/609). The effect of NS-2028 on the angiogenic activity of VEGF was assayed in vivo using the rabbit cornea assay as described previously(40). Briefly, New Zealand White albino rabbits (Charles River, Calco, Como, Italy) were pre-treated with NS-2028 (1 g/l) or vehicle (ethanol) provided in the drinking water for 8 consecutive days and discontinued the day of pellet implantation. Water consumption was 500 ml/day. Slow-release pellets bearing VEGF (300 ng) were prepared in sterile conditions. Rabbits were anesthetized by sodium pentothal (30 mg/kg) and pellets were implanted in micropockets surgically produced in the lower half of the eye in the transparent avascular corneal stroma. Subsequent daily observations of the implants were made for 15 days with a slit lamp stereomicroscope without anaesthesia by a blinded observer. An angiogenic response was scored positive when budding of vessels from the limbal plexus occurred after 3-4 days and capillaries progressed to reach the implanted pellet. Angiogenic activity was expressed as the number of implants exhibiting neovascularization over the total implants studied. Potency was scored by the number of newly formed vessels and by their growth rate. Data were expressed as angiogenesis score, calculated as vessel density x distance from limbus in mm as previously described (40).
Aortic ring vasorelaxant response
Rabbits treated with NS-2028 or vehicle for 8 days, as described above, were sacrificed on day 9 after drug discontinuation by sodium pentothal overdose and the thoracic aorta was cut into 3-3.5 mm-wide transverse rings. Each aortic ring was mounted in an organ bath by means of two triangle-shaped stainless steel wires. The lower wire was fixed to the bottom of the chamber, while the upper wire was connected to the force transducer.
The rings were suspended under a tension of 2 g and isometric force of contraction was measured and recorded on a chart recorder. The preparations were allowed to equilibrate for at least 1 h in a gassed (95%, CO2 5%) Krebs solution (115 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 25 mM NaHCO3, 2.4 mM CaCl2, 1.2 mM MgSO4, 10 mM glucose)
at 37 0 C. Cumulative dose-response curves for Ach (0.01-10 μM) were performed in preparations preconstricted with NA. The maximal force of contraction induced by NA was taken as 100% and the relaxation induced by Ach was referred to this value.
Modified Miles assay
One hr prior to the measurement of vascular leakage mice (C57/Bl6) received 10mg/kg NS-2028 i.p or vehicle. Under anesthesia (ketamine/xylazine), mice were injected i.v.
with Evans blue (30 mg/kg; Sigma-Aldrich). VEGF (300 ng in 15 μl) or saline was injected intradermally into the dorsal surface of the right and left ears, respectively. After 30 min, mice were euthanized and the ears were removed, oven-dried at 55°C, and weighed. Evans blue was then extracted from the ears using 500 μl of formamide for 24 hr at 55°C. Evans blue extravasation into the ear was measured spectrophotometrically at 630 nm using a standard curve of Evans blue in formamide. Results were normalized per tissue weight.
Data Analysis and Statistics
Data are expressed as means ± S.E.M. of the indicated number of observations. Statistical comparisons between groups were performed using ANOVA followed by a post hoc test or Student's t test as appropriate. Differences were considered significant when P < 0.05.
RESULTS

sGC blockade inhibits the angiogenic phenotype of EC
In our first series of experiments we examined the effect of sGC inhibition on VEGF- We next studied the effects of NS-2028 on VEGF-stimulated migration in using two different assays: a modified Boyden chamber and a scratch wound assay (Fig.3 ). In the Boyden chamber assay, NS-2028 inhibited basal cell motility by 50% and abolished VEGF-induced migration (Fig. 3A&B ). In the scratch wound assay, NS-2028 reduced VEGF-induced wound closure; this effect was prominent at the 24 hr time point (Fig. 3C&D ). Our findings suggest that sGC is essential for the expression of the angiogenic phenotype in response to VEGF.
NS-2028 attenuates VEGF-induced EC migration by inhibiting p38 MAPK activation
We next investigated the signalling mechanism involved in the inhibitory action of NS- 4C ) and reduced the motility of cells exposed to the NO-independent sGC activator YC-1 (Fig.4E) . Moreover, consistent with its ability to block VEGF-stimulated motility (Fig.3) , NS-2028 attenuated VEGF-enhanced p38 phosphorylation (Fig.4 A&B) , suggesting that cGMP functions upstream of p38 to induce migration. To prove that elevations in intracellular cGMP can activate p38, cells were treated with the cell membrane permeable analogue of cGMP 8-Br-cGMP (Fig.4F) .
Exposure of cells to 8-Br-cGMP led to a time-dependent increase in p38 and ERK1/2 phosphorylation that reached significance after 10 and 15min of exposure. NS-2028 was capable of reducing the migration triggered by both a NO-dependent (DETA-NO) and a NO-independent (BAY 41-2272) activator of sGC (Fig. 4D) . Overall, our results indicate that p38 is a downstream effector of sGC/cGMP in the signalling pathway of VEGFinduced migration of EC in vitro.
To test the specificity of action of NS-2028, we evaluated its ability to interfere with bFGF-induced migration and sprouting. Exposure of cells to bFGF stimulated their migration in the Boyden chamber assay and promoted wound closure in the scratch wound assay (Fig.5 A, C & D) ; both responses were unaffected by NS-2028 treatment.
Similar results were obtained in the spouting assay, where microvessel formation in response to bFGF was not inhibited by NS-2028 treatment (Fig.5B) .
.
NS-2028 inhibits VEGF-induced angiogenesis in vivo
Having established that sGC is important in VEGF-stimulated angiogenesis in vitro, we sought to determine whether NS-2028 administration could impair the process of VEGFinduced formation of new vessels in vivo. Rabbits receiving NS-2028 in the drinking water exhibited a significant reduction of new vessel formation in the avascular rabbit cornea in response to VEGF pellet implants (Fig. 6A&B ). To our knowledge this is the first report showing that NS-2028 is orally bioavailable. It is worth noting that NS-2028 administration was discontinued at the day of VEGF implantation for practical reasons (the amount of NS-2028 synthesized being the limiting factor) and, thus the contribution of sGC in VEGF-induced angiogenesis might be underestimated. To prove that in spite of early termination of NS-2028 treatment the inhibitor was active after a week, the vasorelaxant responses to Ach were measured in NE pre-constricted aortic rings isolated from rabbits. In these experiments we could document that NS-2028-treated animals exhibited significantly reduced vasodilatory responses compared to vehicle-treated animals ( Fig. 6C) . In view of these results we conclude that sGC is actively involved in VEGF-induced pathways associated with vessel formation.
NS-2028 blocks VEGF-induced vascular leakage in vivo
It is well-known that VEGF increases microvascular permeability which is directly associated with new vessel sprouting under both normal and pathophysiological conditions. To assess the effect of NS-2028 on the ability of VEGF to induce microvascular leakage we used a modified Miles assay. Intradermal injection of VEGF in the mouse ear enhanced vascular permeability as indicated by Evan's blue extravasation.
However, pre-treatment of animals with NS-2028 blunted the VEGF effect (Fig.6D ). Our data are consistent with the hypothesis that sGC is an important effector in the VEGFmediated vascular permeability pathway.
DISCUSSION
The importance of NO production to vascular permeability and angiogenesis has been previously documented(38). Neo-vascularization in response to tissue ischemia, 
